CLEVELAND (BUSINESS WIRE) Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications, announces patient enrollment has begun in the third and final cohort in MATRICS-1, the Phase 2 clinical study evaluating MultiStem® in patients.
Athersys, Inc. , a regenerative medicine company developing MultiStem® cell therapy for critical care indications, announces patient enrollment has begun in the third and final cohort in. | June 1, 2023
Patient Enrollment Begins in Third and Final Cohort of the Phase 2 MATRICS-1 Clinical Study Evaluating Athersys MultiStem® Following Hemorrhagic Trauma streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
If confirmed through genetic sequencing, which will take several days, these will be the first known cases of the omicron variant in Austin-Travis County.